The article talks about a big person named Cathie Wood who has a special box called ARK Innovation ETF that she uses to pick and choose different things. But some of the things in her box lost a lot of value, which means they are not worth as much money as before. The article lists 10 things that lost a lot of value, and their names and how much they lost. Read from source...

- The title is misleading and sensationalized, as it implies that the entire Ark Innovation ETF has seen a sharp decline among its top holdings, when in reality only some of them have. A more accurate title would be "Cathie Wood's Ark Innovation ETF Sees Sharp Decline Among Some Top Holdings".
- The article does not provide any context or explanation for why these particular stocks have declined so drastically, nor does it offer any analysis of their prospects or outlook. This leaves the reader with a one-sided and incomplete picture of the situation.

I have analyzed the article you provided and extracted the following key points:
- Cathie Wood's Ark Innovation ETF (ARKK) has experienced a sharp decline among its top holdings, with 10 of them losing over 90% of their value.
- The most significant losers include Ginkgo Bioworks (-93.4%), Teladoc Health (-93.0%), Pacific Biosciences (-90.2%), 10x Genomics (-85.0%), Unity Technologies (-81.2%), and Verve Therapeutics (-87.6%).
- The article does not provide any information on the reasons for the decline or the future outlook of these companies/ETFs.

Based on this information, I suggest that you consider the following investment recommendations:

1. If you are looking for a high-risk, high-reward strategy, you could buy some of the most beaten-down stocks in the ARKK ETF, such as Ginkgo Bioworks or Teladoc Health, with the expectation that they will recover and reach their initial prices or higher. This would require a lot of research and patience, as these stocks are very volatile and unpredictable. The risk is that you could lose most or all of your investment if the market does not favor them again.
2. If you prefer a more conservative approach, you could avoid investing in any of the companies or ETFs mentioned in the article, as they have shown poor performance and lack of stability. You could instead focus on other sectors or industries that are less risky and more likely to generate consistent returns, such as dividend-paying stocks, bonds, or index funds. The risk is that you may miss out on potential upside if these companies/ETFs rebound in the future.
3. If you want a balanced portfolio that combines both growth and income, you could allocate a small portion of your investment to some of the most promising stocks in the ARKK ETF, such as 10x Genomics or Unity Technologies, while keeping the majority of your assets in safer options. This would allow you to benefit from the upside potential of innovation and disruption, while also protecting yourself from excessive losses. The risk is that you may not achieve the best returns possible if either scenario performs poorly.